Investor Profile: Innogest — Thesis, Cheque Size & How to Apply

Innogest Capital (Innogest SGR) is the Italian venture firm that has spent two decades betting on two fields it knows deeply: healthcare and digital. Founded in 2006 and based in Turin and Milan, with a presence in Geneva and San Francisco, it manages around 200 million euros across its funds and invests at seed and early stage. This profile of Innogest funding covers its thesis, cheque sizes, portfolio and how to get funding from Innogest.

Thesis

Innogest's tagline is "we are investors in companies that make the difference". It claims more than 100 years of cumulative professional experience across the digital and healthcare fields, and it invests through direct equity stakes with close attention to market potential. In medtech it is famously focused: the MedTech Strategist calls it "one of the most active medtech investors around today", betting on cardiovascular with an incubator to supplement its fund investments, while partnering with research centres and technology-transfer offices across Italy and beyond.

Sectors & stage

Two verticals. In healthcare: medical devices, diagnostics and digital health, with particular attention to cardiovascular, neurology and oncology. In digital: foodtech, fintech, fashion-tech and lifestyle. Stage is seed to Series B, with cheques typically between 100,000 dollars and 5 million dollars and an average ticket of 1 to 5 million dollars. Geography is Italy first, with deals in the US and Spain.

Fund size & cheque size

The firm manages investment funds with a total value of about 200 million euros across two funds, with 68 investments recorded. Its second fund counts the European Investment Bank, the European Investment Fund and Fondazione Cariplo among its limited partners. Round sizes in the portfolio database range from about 1.1 to 32 million dollars.

Notable portfolio

Healthcare names include Newronika (the Milan General Hospital spin-off, whose 8.4 million euro round Innogest joined), Affera, Anaconda Biomed and Renovacor. Digital and consumer names include Everli, Sardexpay, Soul-K, MioAssicuratore and Exa Futures.

Partners

Public team listings name Stefano Molino, Teresa Sanseverino, Marco Pinciroli, Giuseppe Donagemma, Simona Roggero, Sergio Maistrello, Marco Millini, Giovanni Leo and Erminia Munao, with Rick Belluzzo associated with the firm. Individual partner titles were not publicly confirmed at the time of writing.

Programs & perks

Innogest runs no public accelerator or credit programme that could be verified. Its structural advantage is the incubator activity in medtech and the network of research centres and technology-transfer offices it partners with, plus institutional backing from the EIB and EIF.

How to apply for funding from Innogest

No open pitch inbox, application form or programme page could be verified for Innogest; the firm's site (innogest.it) could not be read at research time. Founders should use the contact details published on the firm's website.